1 / 12

Lysosomal Storage Diseases Therapeutics Market Insights

Read here the market research report.

PriyaCmi
Download Presentation

Lysosomal Storage Diseases Therapeutics Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. LYSOSOMAL STORAGE DISEASES THERAPEUTICS MARKET ANALYSIS Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End User (Hospitals, Clinics), and By Region (North America Latin America Europe Asia Pacific Middle East Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  3. The global lysosomal storage diseases therapeutics market is estimated to account for US$ 7,217.9 Mn in terms of value in 2019 and is expected to reach US$ 15,734.5 Mn by the end of 2027. • Global Lysosomal Storage Diseases Therapeutics Market: Drivers • North America region held dominant position in the global lysosomal storage diseases therapeutics market in 2018, accounting for 32.4% share in terms of value, followed by Europe.

  4. Restraints • Geographic dispersal of LSDs hampers efforts to understand the disease, given that certain rare diseases are even rarer in some regions. For instance, birth prevalence of LDSs differ considerably between various countries and population groups—Ashkenazi Jewish Ancestry have high prevalence of several genetic diseases, including some LSDs. Also, there is unusually high prevalence of Mucopolysaccharidosis (MPS) VI, GM1 gangliosidosis and fucosidosis in UAE, owing to ethnic isolation.

  5. Market Opportunities R&D in LSDs is expected to offer lucrative growth opportunities for players in the global lysosomal storage diseases therapeutics market. For instance, in February 2020, researchers from BioStrategies LC, State University (U.S.), reported that biodistribution studies in LSD models provide evidence for the theory that the RTB-lectin transports corrective doses of enzymes across the blood–brain barrier for the treatment of central nervous system pathologies. Enzyme replacement therapy segment in the global lysosomal storage diseases therapeutics market was valued at US$ 6,856.2 Mn in 2019 and is expected to reach US$ 14,938.7 Mn by 2027 at a CAGR of 10.0% during the forecast period.

  6. RegulationsNorthAmerica

  7. Market Trends • The cost of therapies for the treatment of LSDs is high. For instance, Elaprase was regarded as one of the most expensive drugs by Forbes Index, which costs US$ 375,000 per year whereas Naglazyme costs US$ 365,000/patient/year. • In the U.S., Medicare and Medicaid programs provide good extent of reimbursement for LSDs. Around 84% of prescription drug plans covered under Medicare part D and part B provide reimbursement for orphan drugs for FDA approved indication. For instance, cost of Fabrazyme therapy reimbursed under Medicare part B is 80% of the allowable amount for Fabrazyme, for beneficiaries who administer Fabrazyme at a physician’s office or as hospital outpatient.

  8. Competitive Landscape • Major players operating in the global lysosomal storage diseases therapeutics market include, Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc. • Key Developments • Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in January 2020, Quest Diagnostics acquired Blueprint Genetics to expand its product portfolio in genetic and rare diseases. • Major players in the market are also focused on adopting collaboration strategies to expand their portfolio. For instance, in 2019, Amicus Therapeutics, Inc. collaborated with the University of Pennsylvania, under which the company received disease-specific worldwide rights to the university’s Next Generation Gene Therapy Technologies from the Wilson Lab for LSDs and other twelve rare diseases.

  9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference https://www.coherentmarketinsights.com/market-insight/lysosomal-storage-diseases-therapeutics-market-3651

  10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related